Neurotoxicity of biologically targeted agents in pediatric cancer trials

Pediatric Neurology

Volumn 46, Issue 4, 2012, Pages 212-221

  Wells, Elizabeth M ^a,b   Nageswara Rao, Amulya A ^a,b,c   Scafidi, Joseph ^a,b   Packer, Roger J ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; INIPARIB; LAPATINIB; LENALIDOMIDE; MK 2206; OLAPARIB; PERIFOSINE; PLACEBO; RAPAMYCIN; RUCAPARIB; SELUMETINIB; SEMAGACESTAT; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VELIPARIB; VISMODEGIB; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOCARCINOMA; ANXIETY; ASTHENIA; ASTROCYTOMA; ATAXIA; BASAL CELL CARCINOMA; BEHCET DISEASE; BILE DUCT CANCER; BLOOD TOXICITY; BLURRED VISION; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROVASCULAR DISEASE; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CONFUSION; CONSCIOUSNESS DISORDER; CONSTIPATION; CRANIAL NEUROPATHY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; EPENDYMOMA; FATIGUE; GLIOBLASTOMA; GLIOMA; GROWTH DISORDER; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LETHARGY; LEUKEMIA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MEDULLOBLASTOMA; METASTASIS; MOTOR NEUROPATHY; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE SPASM; MUSCLE WEAKNESS; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; OPTIC NEURITIS; ORAL DYSESTHESIA; PANCREAS CANCER; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PONTINE GLIOMA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRESYNCOPE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION NECROSIS; REVIEW; SARCOIDOSIS; SEIZURE; SIDE EFFECT; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOLID TUMOR; SOMNOLENCE; SPINAL CORD DISEASE; THROMBOCYTOPENIA; THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AGENTS; HUMANS; NERVOUS SYSTEM NEOPLASMS; NEUROTOXICITY SYNDROMES; PEDIATRICS;

EID: 84859542719     PISSN: 08878994     EISSN: 18735150     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2012.02.006     Document Type: Review

References (109)

1. Nagaswara Rao AA, Scafidi J, Wells EM, Packer RJ. Biologically targeted therapeutics in pediatric brain tumors. Pediatr Neurol 2012;46:203-11.
2. Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008;26:863-9. (Pubitemid 351398077)
3. Lind JS, Lagerwaard FJ, Smit EF, Senan S. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009;74:1391-6.
4. Meyerhardt JA, Stuart K, Fuchs CS, et al. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol 2007;18:1185-9. (Pubitemid 47244364)
5. Jakacki RI, Hamilton M, Gilbertson RJ, et al. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: A Children's Oncology Group phase I consortium study. J Clin Oncol 2008;26:4921-7.
6. Broniscer A, Baker SJ, Stewart CF, et al. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res 2009;15:701-7.
7. Geoerger B, Hargrave D, Thomas F, et al. ITCC (Innovative Therapies for Children With Cancer) European Consortium. Innovative Therapies for Children With Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neurol Oncol 2011;13:109-18.
8. Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (Iressa) monotherapy: Clinical experience in non-small-cell lung cancer. Drug Saf 2004;27:1081-92. (Pubitemid 39647851)
9. Sharp H, Morris JC, Van Waes C, Gius D, Cooley-Zgela T, Singh AK. High incidence of oral dysesthesias on a trial of gefitinib, paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. Am J Clin Oncol 2008;31:557-60.
10. Yan DF, Yan SX, Yang JS, et al. Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: Two case reports and review of the literature. BMC Cancer 2010;10:49.
11. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1864-71.
12. Daw NC, Furman WL, Stewart CF, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: A Children's Oncology Group study. J Clin Oncol 2005;23:6172-80.
13. Geyer JR, Stewart CF, Kocak M, et al. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer 2010;46:3287-93.
14. Furman WL, Navid F, Daw NC, et al. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol 2009;27:4599-604.
15. Pollack IF, Stewart CF, Kocak M, et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: A report from the Pediatric Brain Tumor Consortium. Neurol Oncol 2011;13:290-7.
16. Oakman C, Pestrin M, Zafarana E, Cantisani E, Di Leo A. Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. Cancer Manag Res 2010;2:13-25.
17. Fouladi M, Stewart CF, Blaney SM, et al. Phase I trial of lapatinib in children with refractory CNS malignancies: A Pediatric Brain Tumor Consortium study. J Clin Oncol 2010;28:4221-7.
18. Patel SB, Gojo I, Tidwell ML, Sausville EA, Baer MR. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leuk Lymphoma 2011;52:1211-4.
19. Chen H, Liu KY, Xu LP, et al. Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Chin Med J [Engl] 2011;124:246-52.
20. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group study. J Clin Oncol 2009;27:5175-81.
21. Champagne MA, Capdeville R, Krailo M, et al. Children's Oncology Group phase 1 study: Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a Children's Oncology Group phase 1 study. Clin Cancer Res 2011;17:5113-22.
22. Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report. Neurol Oncol 2007;9:145-60. (Pubitemid 46580316)
23. Shima H, Tokuyama M, Tanizawa A, et al. H. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 2011;159:676-81.
24. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Cerebrovascular accidents in ranibizumab. Ophthalmology 2009;116:362.
25. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncol 2010;49:287-97.
26. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42. (Pubitemid 38702844)
27. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7:475-85. (Pubitemid 46809172)
28. Iwamoto FM, Fine HA. Bevacizumab for malignant gliomas. Arch Neurol 2010;67:285-8.
29. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006;24:1363-9. (Pubitemid 46621999)
30. Kelly PJ, Dinkin MJ, Drappatz J, O'Regan KN, Weiss SE. Unexpected late radiation neurotoxicity following bevacizumab use: A case series. J Neurooncol 2011;102:485-90.
31. Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007;67:323-6. (Pubitemid 46108339)
32. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011;79:1487-95.
33. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
34. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003;21:3542-3.
35. Carden CP, Larkin JM, Rosenthal MA. What is the risk of intracranial bleeding during anti-VEGF therapy? Neurol Oncol 2008;10:624-30.
36. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA 2008;300:2277-85.
37. Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of anti-coagulation use and bevacizumab in patients with glioma. Neurol Oncol 2008;10:355-60.
38. Leighl NB, Bennouna J, Yi J, Moore N, Hambleton J, Hurwitz H. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer 2011;104:413-8.
39. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40.
40. Parekh C, Jubran R, Erdreich-Epstein A, et al. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. J Neurooncol 2011;103:673-80.
41. Narayana A, Kunnakkat S, Chacko-Mathew J, et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neurol Oncol 2010;12:985-90.
42. Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A Pediatric Brain Tumor Consortium study. J Clin Oncol 2010;28:3069-75.
43. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009;52:791-5.
44. Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003;21:2492-9. (Pubitemid 46606330)
45. Kurzrock R, Albitar M, Cortes JE, et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 2004;22:1287-92. (Pubitemid 41079843)
46. Perez-Ruixo JJ, Chen W, Zhang S, Hayes S, Chow A. Exposure-toxicity relationships for tipifarnib in cancer patients. Br J Clin Pharmacol 2007;64:219-32. (Pubitemid 47063250)
47. Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study. J Clin Oncol 2006;24:3651-6. (Pubitemid 46630540)
48. Lustig R, Mikkelsen T, Lesser G, et al. New Approaches to Brain Tumor Therapy CNS Consortium. Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neurol Oncol 2008;10:1004-9.
49. Gore L, Holden SN, Cohen RB, et al. A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors. Ann Oncol 2006;17:1709-17. (Pubitemid 44680894)
50. Widemann BC, Arceci RJ, Jayaprakash N, et al. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group. Pediatr Blood Cancer 2011;56:226-33.
51. Haas-Kogan DA, Banerjee A, Kocak M, et al. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Cancer 2007;110:2535-41.
52. Widemann BC, Salzer WL, Arceci RJ, et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006;24:507-16. (Pubitemid 46630471)
53. Fouladi M, Nicholson HS, Zhou T, et al. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: A Children's Oncology Group study. Cancer 2007;110:2535-41. (Pubitemid 350174941)
54. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 2006;24:e48.
55. Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann. Oncol 2007;18:1745-7. (Pubitemid 47506266)
56. Martin G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 2007;25:35-59.
57. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465-77.
58. Houk BE, Bello CL, Poland B, et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: Results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010;66:357-71.
59. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008;26:3709-14.
60. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. JNCI 2011;103:763-73.
61. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-6. (Pubitemid 351264362)
62. Staehler M, Haseke N, Nuhn P, et al. Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. BJU Int 2011;108:673-8.
63. Dubois SG, Shusterman S, Ingle AM, et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: A Children's Oncology Group study. Clin Cancer Res 2011;17:5113-22.
64. Banerji U, Camidge DR, Verheul HM, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): A phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 2010;16:1613-23.
65. Alvarado Y, Mita MM, Vemulapalli S, Mahalingam D, Mita AC. Clinical activity of mammalian target of rapamycin inhibitors in solid tumors. Target Oncol 2011;6:69-94.
66. Qin W, Tan CY, Huang X, Huang Z, Tao Y, Fu P. Rapamycin-induced posterior reversible encephalopathy in a kidney transplantation patient. Int Urol Nephrol 2011;43:913-6.
67. van de Beek D, Kremers WK, Kushwaha SS, McGregor CG, Wijdicks EF. No major neurologic complications with sirolimus use in heart transplant recipients. Mayo Clin Proc 2009;84:330-2.
68. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006;59:490-8. (Pubitemid 43358069)
69. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-47. (Pubitemid 41115390)
70. Pandya KJ, Dahlberg S, Hidalgo M, et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: A trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007;2:1036-41. (Pubitemid 350059580)
71. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18. (Pubitemid 41103603)
72. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23:5347-56. (Pubitemid 46206988)
73. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:5314-22. (Pubitemid 46206985)
74. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group study. J Clin Oncol 2005;23:5294-304. (Pubitemid 46206983)
75. Chang SM, Wen P, Cloughesy T, et al North American Brain Tumor Consortium and the National Cancer Institute. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005;23:357-61. (Pubitemid 40980358)
76. Campone M, Levy V, Bourbouloux E, et al. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer 2009;100:315-21.
77. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363:1801-11.
78. Hattori Y, Okamoto S, Shimada N, et al. Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: Prognostic factors and unique toxicity profile. Cancer Sci 2008;99:1243-50. (Pubitemid 351676638)
79. Lazzerini M, Martelossi S, Marchetti F, et al. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: Long-term results. Aliment Pharmacol Ther 2007;25:419-27. (Pubitemid 46184455)
80. Lehman TJ. Thalidomide for rheumatic disease: The best of both worlds? Nat Clin Pract Rheumatol 2007;3:308-9. (Pubitemid 46864880)
81. Gilheeney SW, Lyden DC, Sgouros S, et al. A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies. Pediatr Blood Cancer 2007;49:261-5. (Pubitemid 47236214)
82. Dimopoulos M, Spencer A, Attal M, et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32 [Erratum in N Engl J Med 2009;361:544]. (Pubitemid 350146107)
83. Dimopoulos MA, Palumbo A, Attal M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: Consensus statement. Leukemia 2011;25:749-60.
84. Warren KE, Goldman S, Pollack IF, et al. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol 2011;29:324-9.
85. Berg SL, Cairo MS, Russell H, et al. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: A Children's Oncology Group phase I consortium report. J Clin Oncol 2011;29:316-23.
86. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the Hedgehog pathway in advanced basal cell carcinoma. N Engl J Med 2009;361:1164-72.
87. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17:2502-11.
88. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with Hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009;361:1173-8.
89. Shih IM, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007;67:1879-82.
90. Fleisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008;65:1031-8.
91. Schor NF. What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us. Ann Neurol 2011;69:237-9.
92. Barten DM, Meredith JE Jr, Zaczek R, Houston JG, Albright CF. Gamma-secretase inhibitors for Alzheimer's disease: Balancing efficacy and toxicity. Drugs Res Dev 2006;7:87-97.
93. Schaefer EW, Loaiza-Bonilla A, Juckett M, et al. Mayo P2C Phase II Consortium. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009;94:1375-82.
94. Galanis E, Jaeckle KA, Maurer MJ, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group study. J Clin Oncol 2009;27:2052-8 [Erratum in J Clin Oncol 2009;27:3262-3].
95. Ramalingam SS, Maitland ML, Frankel P, et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010;28:56-62.
96. Wise LD, Turner KJ, Kerr JS. Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. Birth Defects Res [B] Dev Reprod Toxicol 2007;80:57-68.
97. Fouladi M, Park JR, Stewart CF, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: A Children's Oncology Group phase I consortium report. J Clin Oncol 2010;28:3623-9.
98. Wolff JE, Kramm C, Kortmann RD, et al. Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol 2008;90:309-14.
99. Su JM, Li XN, Thompson P, et al. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: A Children's Oncology Group report. Clin Cancer Res 2011;17:589-97.
100. Badros A, Golubeva O, Dalal JS. Neurotoxicity of bortezomib therapy in multiple myeloma: A single-center experience and review of the literature. Cancer 2007;110:1042-9. (Pubitemid 47312870)
101. Blaney SM, Bernstein M, Neville K, et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: A Children's Oncology Group study (ADVL0015). J Clin Oncol 2004;22:4804-9 [Erratum in J Clin Oncol 2005;23:248].
102. Horton TM, Pati D, Plon SE, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: A Children's Oncology Group study. Clin Cancer Res 2007;13:1516-22. (Pubitemid 46450443)
103. Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium. Pediatr Blood Cancer 2010;55:254-9.
104. Fanale M, Fayad L, Pro B, et al. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol 2011;154:284-6.
105. Plummer R, Jones C, Middleton M, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008;14:7917-23.
106. Samol J, Ranson M, Scott E, et al. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: A phase I study. Invest New Drugs; 2011. May 18 (Epub ahead of print).
107. Gartner EM, Burger AM, Lorusso PM. Poly(ADP-ribose) polymerase inhibitors: A novel drug class with a promising future. Cancer J 2010;16:83-90.
108. Yokoyama H, Kuroiwa H, Tsukada T, Uchida H, Kato H, Araki T. Poly(ADP-ribose) polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. J Neurosci Res 2010;88:1522-36.
109. Gong X, Schwartz PH, Linskey ME, Bota DA. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology 2011;76:1126-34.